[go: up one dir, main page]

FI20115234A0 - Uusia pyridatsinoni- ja pyridoniyhdisteitä - Google Patents

Uusia pyridatsinoni- ja pyridoniyhdisteitä

Info

Publication number
FI20115234A0
FI20115234A0 FI20115234A FI20115234A FI20115234A0 FI 20115234 A0 FI20115234 A0 FI 20115234A0 FI 20115234 A FI20115234 A FI 20115234A FI 20115234 A FI20115234 A FI 20115234A FI 20115234 A0 FI20115234 A0 FI 20115234A0
Authority
FI
Finland
Prior art keywords
pyridone compounds
pyridazinone
relates
compounds
solvates
Prior art date
Application number
FI20115234A
Other languages
English (en)
Swedish (sv)
Inventor
Marjo Pihlavisto
David Smith
Auni Juhakoski
Ferenc Fulop
Laszlo Lazar
Istvan Szatmari
Ferenc Miklos
Zsolt Szakonyi
Lorand Kiss
Marta Palko
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Priority to FI20115234A priority Critical patent/FI20115234A0/fi
Publication of FI20115234A0 publication Critical patent/FI20115234A0/fi
Priority to NZ616108A priority patent/NZ616108B2/en
Priority to DK12754287.6T priority patent/DK2683711T3/en
Priority to JP2013557146A priority patent/JP5992458B2/ja
Priority to HRP20170584TT priority patent/HRP20170584T1/hr
Priority to US14/003,626 priority patent/US9371290B2/en
Priority to SI201230937T priority patent/SI2683711T1/sl
Priority to PL12754287T priority patent/PL2683711T3/pl
Priority to ES12754287.6T priority patent/ES2630712T3/es
Priority to PCT/FI2012/050220 priority patent/WO2012120195A1/en
Priority to LTEP12754287.6T priority patent/LT2683711T/lt
Priority to AU2012224499A priority patent/AU2012224499B2/en
Priority to CA2832377A priority patent/CA2832377C/en
Priority to EP12754287.6A priority patent/EP2683711B8/en
Priority to TW101107691A priority patent/TWI532731B/zh
Priority to ZA2013/07476A priority patent/ZA201307476B/en
Priority to US15/144,452 priority patent/US9815795B2/en
Priority to US15/729,735 priority patent/US10479771B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI20115234A 2011-03-08 2011-03-08 Uusia pyridatsinoni- ja pyridoniyhdisteitä FI20115234A0 (fi)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FI20115234A FI20115234A0 (fi) 2011-03-08 2011-03-08 Uusia pyridatsinoni- ja pyridoniyhdisteitä
EP12754287.6A EP2683711B8 (en) 2011-03-08 2012-03-06 New pyridazinone and pyridone compounds
ES12754287.6T ES2630712T3 (es) 2011-03-08 2012-03-06 Nuevos compuestos de piridazinona y piridona
LTEP12754287.6T LT2683711T (lt) 2011-03-08 2012-03-06 Nauji piridazinono ir piridono junginiai
JP2013557146A JP5992458B2 (ja) 2011-03-08 2012-03-06 新規ピリダジノンおよびピリドン化合物
HRP20170584TT HRP20170584T1 (hr) 2011-03-08 2012-03-06 Novi spojevi piridazinona i piridona
US14/003,626 US9371290B2 (en) 2011-03-08 2012-03-06 Pyridazinone compounds
SI201230937T SI2683711T1 (sl) 2011-03-08 2012-03-06 Nove spojine piridazinona in piridona
PL12754287T PL2683711T3 (pl) 2011-03-08 2012-03-06 Nowe związki pirydazynonowe i pirydonowe
NZ616108A NZ616108B2 (en) 2011-03-08 2012-03-06 New pyridazinone and pyridone compounds
PCT/FI2012/050220 WO2012120195A1 (en) 2011-03-08 2012-03-06 New pyridazinone and pyridone compounds
DK12754287.6T DK2683711T3 (en) 2011-03-08 2012-03-06 NEW PYRIDAZINON AND PYRIDON COMPOUNDS
AU2012224499A AU2012224499B2 (en) 2011-03-08 2012-03-06 New pyridazinone and pyridone compounds
CA2832377A CA2832377C (en) 2011-03-08 2012-03-06 Pyridazinone and pyridone compounds
TW101107691A TWI532731B (zh) 2011-03-08 2012-03-07 新穎噠嗪酮及吡啶酮化合物
ZA2013/07476A ZA201307476B (en) 2011-03-08 2013-10-07 New pyridazinone and pyridone compounds
US15/144,452 US9815795B2 (en) 2011-03-08 2016-05-02 Pyridazinone and pyridone compounds
US15/729,735 US10479771B2 (en) 2011-03-08 2017-10-11 Pyridazinone and pyridone compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115234A FI20115234A0 (fi) 2011-03-08 2011-03-08 Uusia pyridatsinoni- ja pyridoniyhdisteitä

Publications (1)

Publication Number Publication Date
FI20115234A0 true FI20115234A0 (fi) 2011-03-08

Family

ID=43806445

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115234A FI20115234A0 (fi) 2011-03-08 2011-03-08 Uusia pyridatsinoni- ja pyridoniyhdisteitä

Country Status (15)

Country Link
US (3) US9371290B2 (fi)
EP (1) EP2683711B8 (fi)
JP (1) JP5992458B2 (fi)
AU (1) AU2012224499B2 (fi)
CA (1) CA2832377C (fi)
DK (1) DK2683711T3 (fi)
ES (1) ES2630712T3 (fi)
FI (1) FI20115234A0 (fi)
HR (1) HRP20170584T1 (fi)
LT (1) LT2683711T (fi)
PL (1) PL2683711T3 (fi)
SI (1) SI2683711T1 (fi)
TW (1) TWI532731B (fi)
WO (1) WO2012120195A1 (fi)
ZA (1) ZA201307476B (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20115234A0 (fi) * 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2014279863A1 (en) 2013-06-12 2016-01-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
WO2017098236A1 (en) 2015-12-07 2017-06-15 Proximagen Limited Vap-1 inhibitors for treating pain
WO2017148519A1 (en) 2016-03-03 2017-09-08 Boehringer Ingelheim International Gmbh Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as aoc3 inhibitors
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US12178809B2 (en) 2018-10-29 2024-12-31 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US20250194601A1 (en) * 2022-03-30 2025-06-19 Ishihara Sangyo Kaisha, Ltd. Pyridazinone compound or salt thereof and pest control agent containing it
CA3265895A1 (en) * 2022-08-25 2024-02-29 The Hospital For Sick Children PYRIDAZINONE COMPOUNDS MODULATING MUTANT PROTEINS FOR THE TREATMENT OF RESPIRATORY DISEASES
CN117143074B (zh) * 2023-08-31 2025-08-29 四川大学 3-苄氧基-6-吡啶基哒嗪类化合物及其制备方法和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59199681A (ja) 1983-04-26 1984-11-12 Ube Ind Ltd １，２，４−トリアゾ−ル−３−カルボン酸アミド類の製造法
CN1450998A (zh) 2000-07-05 2003-10-22 拜奥泰治疗公司 含铜的胺氧化酶的抑制剂
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
JP2003040872A (ja) * 2001-07-27 2003-02-13 Fuji Photo Film Co Ltd ピリダジノン化合物、及び該ピリダジノン化合物の互変異性体
US7125901B2 (en) 2003-01-27 2006-10-24 Astellas Pharma Inc. Thiazole derivatives
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
CN1794988B (zh) 2003-03-31 2010-07-28 株式会社·R-技术上野 用于治疗血管渗透性过高疾病的组合物
WO2005008319A1 (en) 2003-07-17 2005-01-27 Koninklijke Philips Electronics N.V. Micro-chanel cooling for video projectors (“beamers”)
JP2007501802A (ja) 2003-08-08 2007-02-01 ラ ホヤ ファーマシューティカル カンパニー 疾患の処置に有用な、セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）およびｖａｐ−１媒介性接着のインヒビター
EP2251327B1 (en) 2003-11-19 2014-02-12 Array Biopharma, Inc. Heterocyclic inhibitors of mek
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2556914A1 (en) 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
KR20070050932A (ko) 2004-07-27 2007-05-16 가부시키가이샤 아루떼꾸 우에노 Ｖａｐ―１ 억제 활성을 가지는 티아졸 유도체
US20080015202A1 (en) 2004-09-09 2008-01-17 Astellas Pharma Inc. Thiazole Derivatives Having Vap-1 Inhibitory Activity
JPWO2006082872A1 (ja) * 2005-02-04 2008-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 １−（ピペリジン−４−イル）−１ｈ−インドール誘導体
WO2006094201A2 (en) 2005-03-02 2006-09-08 La Jolla Pharmaceutical Company Semicarbazide-sensitive amide oxidase inhibitors
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
US8232274B2 (en) * 2007-03-15 2012-07-31 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
NZ585528A (en) 2007-11-21 2012-08-31 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100015567A1 (en) 2008-07-18 2010-01-21 Jean-Jacques Elbaz Dental Hygiene Tool
HUE025381T2 (en) * 2008-09-11 2016-02-29 Pecsi Tudomanyegyetem Compounds for the inhibition of SSAO / VAP-1 and their use for the treatment and prevention of diseases
JP5613671B2 (ja) 2008-09-16 2014-10-29 プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． 新規化合物ｉｉ
CA2737527C (en) 2008-09-16 2015-12-29 Proximagen Limited 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds useful as inhibitors of ssao activity
EP2376490B1 (en) 2008-12-04 2013-01-23 Proximagen Limited Imidazopyridine compounds
SG172981A1 (en) 2009-01-26 2011-08-29 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
FI20115234A0 (fi) * 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä

Also Published As

Publication number Publication date
CA2832377C (en) 2020-08-04
ES2630712T3 (es) 2017-08-23
US9371290B2 (en) 2016-06-21
AU2012224499B2 (en) 2016-09-01
HRP20170584T1 (hr) 2017-06-16
TWI532731B (zh) 2016-05-11
EP2683711A4 (en) 2014-07-30
EP2683711B1 (en) 2017-02-01
US10479771B2 (en) 2019-11-19
SI2683711T1 (sl) 2017-08-31
NZ616108A (en) 2015-08-28
ZA201307476B (en) 2014-06-25
US20140024648A1 (en) 2014-01-23
WO2012120195A1 (en) 2012-09-13
EP2683711B8 (en) 2017-08-23
CA2832377A1 (en) 2012-09-13
US20180029995A1 (en) 2018-02-01
JP2014507460A (ja) 2014-03-27
AU2012224499A1 (en) 2013-10-24
EP2683711A1 (en) 2014-01-15
LT2683711T (lt) 2017-06-26
US20160244414A1 (en) 2016-08-25
TW201247642A (en) 2012-12-01
US9815795B2 (en) 2017-11-14
PL2683711T3 (pl) 2018-01-31
DK2683711T3 (en) 2017-05-08
JP5992458B2 (ja) 2016-09-14

Similar Documents

Publication Publication Date Title
FI20115234A0 (fi) Uusia pyridatsinoni- ja pyridoniyhdisteitä
UA109010C2 (en) Morpholino pyrividines and their use in therapy
GEP201606555B (en) Compounds and compositions for modulating egfr activity
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
GEAP202213376A (en) Inhibitors of influenza viruses replication
UA111770C2 (uk) Інгібітори бромдомену
PH12012500752A1 (en) Benzimidazole-imidazole derivatives
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
JOP20130256B1 (ar) مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي
MX2013004491A (es) Boronatos como inhibidores de arginasa.
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
BR112014001801A2 (pt) indazóis
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MY172924A (en) Neprilysin inhibitors
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
EA201401351A1 (ru) Производные бензимидазол-пролина
MX335941B (es) Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c.

Legal Events

Date Code Title Description
FD Application lapsed